ロード中...
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
BACKGROUND: Anti-drug antibodies (ADAs) to bococizumab were detected in > 40% of subjects in the SPIRE lipid-lowering trials. The risk of cross-reactivity between anti-bococizumab antibodies and other approved anti-proprotein convertase subtilisin/kexin type-9 (PCSK9) monoclonal antibodies (mAbs)...
保存先:
| 出版年: | BioDrugs |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6790354/ https://ncbi.nlm.nih.gov/pubmed/31529318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-019-00375-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|